NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

頭孢菌素藥物的全球市場(2021年∼2028年)

Global Cephalosporin Drugs Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1022286
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
頭孢菌素藥物的全球市場(2021年∼2028年) Global Cephalosporin Drugs Market - 2021-2028
出版日期: 2021年08月06日內容資訊: 英文 180 Pages
簡介

頭孢菌素類藥物屬於β-內醯胺類藥物,透過干擾細菌細胞壁的合成起作用。其中一些是口服給藥,但大多數是透過腸胃外途徑給藥。通常是第二選擇性抗生素,主要用於肺炎、敗血症、腦膜炎、鼻竇炎和UTI治療。儘管作為二線用途,頭孢菌素還具有更廣泛的活性,並且比青黴素更有效。

本報告提供全球頭孢菌素藥物市場的相關調查,市場規模,機會和影響,成長及阻礙因素,COVID-19的影響,各世代、類型、劑型、適應症、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 全球頭孢菌素藥物市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球頭孢菌素藥物市場-市場定義和概要

第3章 全球頭孢菌素藥物市場-摘要整理

  • 各世代的市場明細
  • 各類型的市場明細
  • 各劑型市場明細
  • 各適應症市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 全球頭孢菌素藥物市場-市場動態

  • 影響市場的要素
    • 成長要素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球頭孢菌素藥物市場-產業分析

  • 波特的五力分析
  • PEST分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球頭孢菌素藥物市場-COVID-19分析

  • 市場上的Covid-19分析
    • COVID-19前的市場方案
    • 目前市場方案
    • COVID-19後或今後方案
  • Covid-19的價格趨勢
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球頭孢菌素藥物市場-各類型

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 非專利
  • 品牌

第8章 全球頭孢菌素藥物市場-各世代

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 第5代頭孢菌素
  • 第1代頭孢菌素
  • 第2代頭孢菌素
  • 第3代頭孢菌素
  • 第4代頭孢菌素

第9章 全球頭孢菌素藥物市場-各劑型

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 注射
  • 口服

第10章 全球頭孢菌素藥物市場-適應症

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 呼吸道感染疾病
  • 皮膚感染疾病
  • 耳朵感染疾病
  • 細菌感染
  • 尿道感染
  • 性感染疾病
  • 鼻竇感染疾病
  • 外科性預防
  • 其他(腦膜炎,急性腹症,骨盆內感染疾病)

第11章 全球頭孢菌素藥物市場-各流通管道

  • 簡介
    • 市場規模分析及與前一年同期比較成長分析
    • 市場魅力指數
  • 零售藥局
  • 醫院藥局
  • 線上藥局

第12章 全球頭孢菌素藥物市場-各地區

  • 簡介
    • 市場規模分析(2018-2028),及與前一年同期比較成長分析(2020-2028)
    • 市場魅力指數
  • 北美
    • 簡介
    • 各主要地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各世代:市場規模分析,及與前一年同期比較成長分析
    • 各適應症:市場規模分析,及與前一年同期比較成長分析
    • 各劑型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 歐洲
    • 簡介
    • 各主要地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各世代:市場規模分析,及與前一年同期比較成長分析
    • 各適應症:市場規模分析,及與前一年同期比較成長分析
    • 各劑型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 南美
    • 簡介
    • 各主要地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各世代:市場規模分析,及與前一年同期比較成長分析
    • 各適應症:市場規模分析,及與前一年同期比較成長分析
    • 各劑型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 亞太地區
    • 簡介
    • 各主要地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各世代:市場規模分析,及與前一年同期比較成長分析
    • 各適應症:市場規模分析,及與前一年同期比較成長分析
    • 各劑型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析
    • 各國:市場規模分析,及與前一年同期比較成長分析
  • 中東和非洲
    • 簡介
    • 各主要地區的動態
    • 各類型:市場規模分析,及與前一年同期比較成長分析
    • 各世代:市場規模分析,及與前一年同期比較成長分析
    • 各適應症:市場規模分析,及與前一年同期比較成長分析
    • 各劑型:市場規模分析,及與前一年同期比較成長分析
    • 各流通管道:市場規模分析,及與前一年同期比較成長分析

第13章 全球頭孢菌素藥物市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 創新的技術的企業
  • Start-Ups企業

第14章 全球頭孢菌素藥物市場-企業簡介概要

  • Novartis AG
    • 企業概要
    • 產品系列、概要
    • 要點
    • 財務概要
  • Astellas Pharma Inc
  • Baxter International
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals
  • Macleods Pharmaceuticals Ltd
  • Mankind Pharma
  • Merck & Co. Inc
  • Teva Pharmaceuticals
  • Shionogi & Co. Ltd

第15章 全球頭孢菌素藥物市場-DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMPH3820

Cephalosporin Drugs Market Overview

The global cephalosporin drugs market size was valued US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Cephalosporin drugs are part of the beta-lactams group and they work by interfering with the synthesis of the bacterial cell wall. Some of them are given orally, but most are given by parenteral route. They are typically the second-choice antibiotic, and mainly used in pneumonia, septicemia, meningitis, sinusitis, and UTI treatment. Despite their second-line usage, cephalosporins also have a broader spectrum of activity and are more potent than penicillin.

Cephalosporin Drugs Market Dynamics

The cephalosporin drugs market growth is driven by the rising demand for anti-microbials in various indications, the increasing prevalence of infectious diseases, the increase in funding for the development of antibiotics, increased consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.

Increasing prevalence of infectious diseases is expected to drive the growth in the forecast period

Increasing prevalence of infectious diseases is expected drive the market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2019, a total of 8,920 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.7 cases per 100,000 population. As per the US Department of Health & Human Services report 2020, about 37,832 people in the United States were diagnosed with HIV in 2018, and 38,000 new HIV infections still occur in the United States. Moreover, it has also been reported that there is a rapid spread of various infectious diseases fueling the market growth.

The rising number of clinical trials for R&D is expected to drive the growth in the forecast period

The rising number of clinical trials for R&D of cephalosporin drugs is also expected to boost the growth of the cephalosporin drugs market over the forecast period. For example, in September 2018, the National Institutes of Health (NIH) granted USD 9.4 million for establishing the Center for Biomedical Research Excellence (COBRE) to address the worldwide threat of drug-resistant pathogens.

Moreover, companies are involved in the strategic development of new products. For instance, in April 2018, Basilea Pharmaceutica Ltd announced that its partner Avir Pharma Inc. launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Canada. Therefore, all these factors may help the cephalosporin drugs market witness fast growth over the forecast period.

Increasing Food and Drug Administration (FDA) recalls is hindering the market growth

For example, in June 2019, Lupin Limited recalled 18,604 bottles (60 ml) of Cefdinir (Cephalosporin) for Oral Suspension, used for the treatment of bacterial infections, from the U.S. market. Furthermore, in January 2019, the company announced a recall of 287,784 bottles of Cefdinir for Oral Suspension in the U.S. due to CGMP (Current Good Manufacturing Practice) deviations.

COVID-19 Impact Analysis

The coronavirus (COVID-19) pandemic and resulting lockdown in various countries across the globe have impacted major companies' financial status. Various studies have found that the higher cephalosporin consumption rate and use ratio have lower morbidity and mortality caused by COVID-19 than other antibacterials. For example, according to a research study by Hisaya Tanioka et aol., published in BMJ Journal October 2020, the study results found that penicillins should be avoided use under the condition in COVID-19. Empirical treatment with neuraminidase inhibitors and the combination of cephalosporins and macrolides or quinolones are suggested to be an effective treatment for COVID-19. However, cephalosporins inhibit the SARS-CoV-2, and the study results and the compelling cases imply that cephalosporins may work against the SARS-CoV-2 virus. Also, the cephalosporins combined with macrolides and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore, there are in vitro and in vivo studies going on to evaluate the potential of generations of cephalosporin for COVID-19.

Cephalosporin Drugs Market Segment Analysis

The fifth-generation segment is expected to hold largest share in this market segment

Fifth-generation cephalosporin drugs are found to be developed in the lab to target resistant strains of bacteria specifically. They are ceftobiprole, ceftaroline, and ceftolozane. In these, ceftobiprole is found to be effective against methicillin-resistant staphylococcus aureus (MRSA).

For instance, according to the UNAIDS, during 2019, the number of new HIV/AIDS cases found globally was around 1.7 million, and about 38 million people were living with HIV globally in the same year.

Ceftobiprole has antipseudomonal characteristics that appear to be less susceptible to the development of resistance. Ceftaroline has also been described as the fifth-generation cephalosporin but does not have the antipseudomonal or VRE coverage of ceftobiprole. The fifth-generation cephalosporins are not active against Pseudomonas species. The market is increasing as it has opened gates for an alternative to treat complicated intra-abdominal infections and complicated urinary tract infections. Moreover, ceftolozane is also combined with the B-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all B-lactam antibiotics unless this enzyme is inhibited. Thus, the rising use of combination therapies may drive the market during the forecast period.

For instance, in March 2018, Basilea Pharmaceutica Ltd partnered with Grupo Biotoscana S.L. had launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Argentina. Also, there has been a notable increase in the fifth-generation cephalosporin drugs such as ceftobiprole and ceftaroline that have been attributed to their ability to kill a wide range of bacteria. Thus, it is expected to drive segment growth over the forecast period due to the aforementioned factors.

The generic cephalosporin drugs segment is expected to hold largest share in this market segment

The generic cephalosporin drugs segment is expected to exhibit the largest growth during the forecast period, as these drugs are available at a very lower cost than branded drugs. Moreover, the pharmacological effects of generic drugs are the same as those of their brand-name counterparts.

The injection segment is expected to hold largest share in this market segment

The injection is the most preferred route of drug administration due to quick drug delivery. Intravenous (IV) cephalosporins are used for more severe infections. This is because IV antibiotics reach the tissues faster, making a big difference if a patient has a serious infection, such as meningitis.

The respiratory tract infections segment is expected to hold largest share in this market segment

The increasing prevalence of respiratory tract infections worldwide is expected to boost the segment growth. For instance, according to the report of The Global Impact of Respiratory Disease in 2017, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for over 4 million fatalities, annually.

The retail pharmacies segment is expected to hold largest share in this market segment

The retail Pharmacies segment is expected to dominate during the forecast period. Cephalosporin drugs are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost market growth.

Cephalosporin Drugs Market Geographical Analysis

Asia-Pacific region holds the largest market share of global cephalosporin drugs market

Asia-Pacific region is expected to witness the highest growth due to the rising incidence of infectious diseases, rising healthcare expenditure, and a large population base. Moreover, cefuroxime is a second-generation cephalosporin antibiotic that has a broad-spectrum activity and is commonly used to treat the upper and lower respiratory tract infections, Lyme disease, and genitourinary tract infections. It is readily available and affordable, and it exists in both oral and parenteral forms.

The COVID-19 pandemic has shown a slight impact on this market as the cephalosporins have not proven effective against viruses. B-lactam antibiotics, including cephalosporins, have a bacteriostatic effect. The bacteriostatic action means the action of suppressing the growth of bacteria. B-lactam antibiotics act by inhibiting peptidoglycan synthase, which is an enzyme required for synthesizing bacterial cell walls.

In China, tuberculosis is the most leading cause of death due to infectious diseases among adults. For example, according to the World Health Organization, in 2019, 8,33,000 people fell ill with tuberculosis in China. Further, China is still among the 30 high-burden tuberculosis countries globally, and tuberculosis remains a public health concern.

Cephalosporin Drugs Market Competitive Landscape

The global cephalosporin drugs market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd, Mankind Pharma, Merck & Co. Inc., Novartis International AG and Teva Pharmaceuticals, Shionogi & Co. Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, In February 2020, Shionogi & Co. Ltd announced that FETROJA (cefiderocol) was now available in the United States for patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs). FETROJA (cefiderocol) is a cephalosporin antibiotic with a novel mechanism for penetrating the outer cell membrane of Gram-negative pathogens by acting as a siderophore.

Cephalosporin Drugs Market Key Companies to Watch

Novartis AG

Overview: Novartis AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It operates business through two divisions: Innovative medicine, Sandoz. Made up of two business units - Novartis Pharmaceuticals which includes Novartis Gene Therapies, and Novartis Oncology - our Innovative Medicines Division commercializes innovative patented medicines to enhance health outcomes for patients and healthcare professionals. Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. The company strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science.

Product Portfolio: The company portfolio includes Oncology, Cardiovascular, Renal and Metabolic Medicine, Immunology, Dermatology, Ophthalmology, Neuroscience, Respiratory.

Key developments: In February 2021, Novartis' generics division Sandoz signed an agreement with British drugmaker GlaxoSmithKline (GSK) to acquire its cephalosporin antibiotics brands for up to USD 500 million.

Why Purchase the Report?

  • Visualize the composition of the cephalosporin drugs market segmentation by generation, type, formulation, indication, distribution channel and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in cephalosporin drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of cephalosporin drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global cephalosporin drugs market report would provide an access to an approx. 77 market data table, 77 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Cephalosporin Drugs Market - By Generation

  • First-generation Cephalosporin
  • Second-generation Cephalosporin
  • Third-generation Cephalosporin
  • Fourth-generation Cephalosporin
  • Fifth-generation Cephalosporin

Global Cephalosporin Drugs Market - By Type

  • Branded Cephalosporin Drugs
  • Generic Cephalosporin Drugs

Global Cephalosporin Drugs Market - By Indication

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Bacterial Infection
  • Urinary Tract Infection
  • Sexually Transmitted Infection
  • Sinus Infection
  • Surgical Prophylaxis
  • Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)

Global Cephalosporin Drugs Market - By Formulation

  • Oral
  • Injection

Global Cephalosporin Drugs Market - By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Cephalosporin Drugs Market - By Region

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • South America

Table of Contents

1. Global Cephalosporin Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cephalosporin Drugs Market - Market Definition and Overview

3. Global Cephalosporin Drugs Market - Executive Summary

  • 3.1. Market Snippet by Generation
  • 3.2. Market Snippet by Type
  • 3.3. Market Snippet by Formulation
  • 3.4. Market Snippet by Indication
  • 3.5. Market Snippet by Distribution Channel
  • 3.6. Market Snippet by Region

4. Global Cephalosporin Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of infectious diseases
      • 4.1.1.2. The rising number of clinical trials for R&D
    • 4.1.2. Restraints:
      • 4.1.2.1. Increasing Food and Drug Administration (FDA) recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cephalosporin Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. PEST Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Cephalosporin Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Cephalosporin Drugs Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Generic Cephalosporin Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Branded Cephalosporin Drugs

8. Global Cephalosporin Drugs Market - By Generation

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 8.1.2. Market Attractiveness Index, By Generation
  • 8.2. Fifth-generation Cephalosporin*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. First-generation Cephalosporin
  • 8.4. Second-generation Cephalosporin
  • 8.5. Third-generation Cephalosporin
  • 8.6. Fourth-generation Cephalosporin

9. Global Cephalosporin Drugs Market - By Formulation

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 9.1.2. Market Attractiveness Index, By Formulation
  • 9.2. Injection*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Oral

10. Global Cephalosporin Drugs Market - By Indication

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.1.2. Market Attractiveness Index, By Indication
  • 10.2. Respiratory Tract Infection*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Skin Infection
  • 10.4. Ear Infection
  • 10.5. Bacterial Infection
  • 10.6. Urinary Tract Infection
  • 10.7. Sexually Transmitted Infection
  • 10.8. Sinus Infection
  • 10.9. Surgical Prophylaxis
  • 10.10. Others (Meningitis, Acute Abdomen Infection, and Pelvic Infection)

11. Global Cephalosporin Drugs Market - By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel Segment
    • 11.1.2. Market Attractiveness Index, By Distribution channel Segment
  • 11.2. Retail Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 11.3. Hospital Pharmacies
  • 11.4. Online Pharmacies

12. Global Cephalosporin Drugs Market - By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Generation
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Global Cephalosporin Drugs Market - Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. Key Companies to Watch
  • 13.5. Company with disruptive technology
  • 13.6. Start Up Companies

14. Global Cephalosporin Drugs Market- Company Profiles

  • 14.1. Novartis AG*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Astellas Pharma Inc
  • 14.3. Baxter International
  • 14.4. F. Hoffmann-La Roche AG
  • 14.5. GlaxoSmithKline PLC
  • 14.6. Lupin Pharmaceuticals
  • 14.7. Macleods Pharmaceuticals Ltd
  • 14.8. Mankind Pharma
  • 14.9. Merck & Co. Inc
  • 14.10. Teva Pharmaceuticals
  • 14.11. Shionogi & Co. Ltd

LIST NOT EXHAUSTIVE

15. Global Cephalosporin Drugs Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us